Cerity Partners LLC Has $1.45 Million Stock Holdings in Exact Sciences Corporation (NASDAQ:EXAS)

Cerity Partners LLC raised its holdings in Exact Sciences Corporation (NASDAQ:EXAS) by 24.0% during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 33,598 shares of the medical research company’s stock after purchasing an additional 6,508 shares during the quarter. Cerity Partners LLC’s holdings in Exact Sciences were worth $1,454,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the company. Price T Rowe Associates Inc. MD raised its position in shares of Exact Sciences by 74.7% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 5,760,241 shares of the medical research company’s stock worth $323,669,000 after acquiring an additional 2,462,165 shares in the last quarter. Capital World Investors grew its stake in shares of Exact Sciences by 10.7% in the 4th quarter. Capital World Investors now owns 17,537,617 shares of the medical research company’s stock valued at $985,439,000 after buying an additional 1,696,321 shares during the period. Mackenzie Financial Corp boosted its stake in Exact Sciences by 107.7% during the 4th quarter. Mackenzie Financial Corp now owns 2,919,325 shares of the medical research company’s stock valued at $164,037,000 after purchasing an additional 1,513,873 shares during the last quarter. Norges Bank acquired a new position in Exact Sciences during the 4th quarter valued at about $50,625,000. Finally, T. Rowe Price Investment Management Inc. boosted its stake in shares of Exact Sciences by 25.8% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 4,269,823 shares of the medical research company’s stock worth $239,922,000 after buying an additional 876,985 shares during the last quarter. Institutional investors and hedge funds own 88.82% of the company’s stock.

Insider Transactions at Exact Sciences

In other Exact Sciences news, Director Katherine S. Zanotti sold 3,207 shares of Exact Sciences stock in a transaction on Friday, June 13th. The shares were sold at an average price of $53.20, for a total value of $170,612.40. Following the sale, the director directly owned 72,759 shares in the company, valued at approximately $3,870,778.80. The trade was a 4.22% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 1.20% of the company’s stock.

Exact Sciences Price Performance

Shares of EXAS opened at $48.36 on Tuesday. The company has a market capitalization of $9.12 billion, a P/E ratio of -8.78, a price-to-earnings-growth ratio of 10.77 and a beta of 0.95. The company has a quick ratio of 2.38, a current ratio of 2.73 and a debt-to-equity ratio of 0.97. The firm has a 50 day moving average of $54.33 and a 200 day moving average of $50.84. Exact Sciences Corporation has a twelve month low of $39.97 and a twelve month high of $72.83.

Exact Sciences (NASDAQ:EXAS) last issued its quarterly earnings results on Thursday, May 1st. The medical research company reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.37) by $0.16. The business had revenue of $706.79 million for the quarter, compared to analysts’ expectations of $688.58 million. Exact Sciences had a negative net margin of 36.06% and a negative return on equity of 3.75%. The company’s revenue was up 10.9% compared to the same quarter last year. During the same quarter last year, the company posted ($0.60) EPS. As a group, equities research analysts anticipate that Exact Sciences Corporation will post -0.58 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on EXAS shares. Guggenheim reaffirmed a “buy” rating and issued a $60.00 price target on shares of Exact Sciences in a report on Friday, April 11th. Mizuho started coverage on shares of Exact Sciences in a report on Thursday, April 10th. They issued an “outperform” rating and a $60.00 price target on the stock. Robert W. Baird boosted their target price on shares of Exact Sciences from $69.00 to $72.00 and gave the company an “outperform” rating in a report on Friday, May 2nd. Evercore ISI boosted their target price on shares of Exact Sciences from $66.00 to $68.00 and gave the company an “outperform” rating in a report on Tuesday, July 8th. Finally, Royal Bank Of Canada boosted their target price on shares of Exact Sciences from $52.00 to $54.00 and gave the company a “sector perform” rating in a report on Friday, May 2nd. Two research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $70.50.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.